“They gave us a tough fight.” Pithy words from a senior executive at a multinational pharma company sums up the point. His reference is to BSV, formerly Bharat Serums and Vaccines, which for a large part of its four decades of existence, quietly grew selling specialised drugs, mostly in the gynaecology segment.
That quietness was shaken six months ago, replaced by loud headlines. Controlled by US-based private-equity (PE) firm Advent.